BR0307016A - ácidos 3-(imidazolil)-2-alcoxipropanóicos - Google Patents

ácidos 3-(imidazolil)-2-alcoxipropanóicos

Info

Publication number
BR0307016A
BR0307016A BR0307016-6A BR0307016A BR0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A
Authority
BR
Brazil
Prior art keywords
imidazolyl
acids
alkyl
hydrogen
optionally substituted
Prior art date
Application number
BR0307016-6A
Other languages
English (en)
Inventor
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307016A publication Critical patent/BR0307016A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"áCIDOS 3-(IMIDAZOLIL)-2-ALCOXIPROPANóICOS". A presente invenção refere-se a novos compostos de acordo com a fórmula (I), em que n é 0-3, R^ 1^ é alquila C~ 1-6~, alquenila C~ 2-6~, ou alquinila C~ 2-6~ opcionalmente substituídas, heterociclo, heterociclo aromático, arila ou hidrogênio e R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^, R^ 7^,R^ 8^ e R^ 9^ são independentemente selecionados, cada um, a partir de hidrogênio e alquila C~ 1-6~ opcionalmente substituída, ou R^ 5^ e R^ 8^ são uma cadeia de alquileno. Eles são úteis no tratamento de condições trombóticas e outras patrologias associadas com a deposição de fibrina.
BR0307016-6A 2002-01-22 2003-01-10 ácidos 3-(imidazolil)-2-alcoxipropanóicos BR0307016A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
BR0307016A true BR0307016A (pt) 2004-11-03

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307016-6A BR0307016A (pt) 2002-01-22 2003-01-10 ácidos 3-(imidazolil)-2-alcoxipropanóicos

Country Status (24)

Country Link
EP (1) EP1467731A1 (pt)
JP (1) JP2005520811A (pt)
KR (1) KR20040077775A (pt)
CN (1) CN1620291A (pt)
AP (1) AP2004003084A0 (pt)
AR (1) AR038197A1 (pt)
BR (1) BR0307016A (pt)
CA (1) CA2472238A1 (pt)
EA (1) EA200400716A1 (pt)
EC (1) ECSP045200A (pt)
HR (1) HRP20040659A2 (pt)
IL (1) IL162677A0 (pt)
IS (1) IS7310A (pt)
MA (1) MA27167A1 (pt)
MX (1) MXPA04006573A (pt)
NO (1) NO20043457L (pt)
OA (1) OA12756A (pt)
PA (1) PA8563501A1 (pt)
PE (1) PE20030929A1 (pt)
PL (1) PL371487A1 (pt)
TN (1) TNSN04121A1 (pt)
TW (1) TW200302094A (pt)
UY (1) UY27615A1 (pt)
WO (1) WO2003061652A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
CA2604912A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
US20110213143A1 (en) 2008-10-29 2011-09-01 Taisho Pharmaceutical Co., Ltd. Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
ES2608779T3 (es) * 2010-03-18 2017-04-17 Daiichi Sankyo Company, Limited Derivado de ácido ciclopropanocarboxílico
DK2548871T3 (da) * 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
WO2014198620A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
KR102616949B1 (ko) 2017-09-14 2023-12-22 다이이찌 산쿄 가부시키가이샤 고리형 구조를 갖는 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
CN1443173A (zh) * 2000-08-17 2003-09-17 辉瑞大药厂 作为TAFIa抑制剂的取代的咪唑

Also Published As

Publication number Publication date
UY27615A1 (es) 2003-08-29
TW200302094A (en) 2003-08-01
PA8563501A1 (es) 2004-08-31
AR038197A1 (es) 2005-01-05
EP1467731A1 (en) 2004-10-20
IL162677A0 (en) 2005-11-20
WO2003061652A8 (en) 2004-09-10
CA2472238A1 (en) 2003-07-31
MA27167A1 (fr) 2005-01-03
HRP20040659A2 (en) 2004-10-31
MXPA04006573A (es) 2004-10-04
KR20040077775A (ko) 2004-09-06
WO2003061652A1 (en) 2003-07-31
CN1620291A (zh) 2005-05-25
AP2004003084A0 (en) 2004-09-30
OA12756A (en) 2006-07-03
IS7310A (is) 2004-06-14
TNSN04121A1 (en) 2006-06-01
ECSP045200A (es) 2004-08-27
EA200400716A1 (ru) 2004-12-30
PL371487A1 (en) 2005-06-13
JP2005520811A (ja) 2005-07-14
PE20030929A1 (es) 2003-11-05
NO20043457L (no) 2004-08-19

Similar Documents

Publication Publication Date Title
NO20020725D0 (no) Celleadhesjonsinhibitorer
NO20065178L (no) Tienopyridinderivater
ATE386043T1 (de) Metallocene und von ihnen abgeleitete katalysatorzusammensetzungen
NO20050065L (no) Kjemiske forbindelser
DE60213452D1 (de) Metallocene und verfahren zur herstellung von propylenpolymeren
EP1254895A4 (en) CYCLIC NITROGEN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0307016A (pt) ácidos 3-(imidazolil)-2-alcoxipropanóicos
DE60239170D1 (de) Bicyclische Verbindungen
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
DE59509910D1 (de) Verfahren zur Herstellung von Alkylhydrogenchlorsilanen
BRPI0415073A (pt) azaciclos n-substituìdos
NO20005301L (no) Pyrrolidiner som inhibitorer av neuraminidaser
DE69915514D1 (de) Prenyltransferase-inhibitoren
ATE279476T1 (de) Silikonhaltige zusammensetzungen für die behandlung von wollematerialien
TR200002485T2 (tr) N-Sülfonil ve N-Sülfinil Fenilglisinamid
DE60013515D1 (de) 4-Arylpiperidinderivate zur Behandlung von Pruritus
BR9714436A (pt) Processo para produção de derivados de imidazol
DOP2003000564A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
DE50206142D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate
GT200300007A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
DOP2003000560A (es) Acidos 3-(imidazolil)-2-aminopropanoicos
TH40965A (th) ตัวเร่งปฏิกิริยาสำหรับโพลิเมอไรเซชันแอลฟา-โอเลฟินที่มีสารประกอบอะมิโนไซเลนที่ถูกแทนที่

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.